Teligent announced the launch of Cefotan (cefotetan for injection) for the treatment of susceptible lower respiratory tract or urinary tract, skin and skin structure, bone and joint, gynecologic, intra-abdominal infections; and for use in surgical prophylaxis.
Cefotan was initially discontinued by AstraZeneca in 2014; this approval by the Food and Drug Administration (FDA) will help address the shortage in treatment.
The bactericidal action of Cefotan results from cell wall synthesis inhibition. Cefotan has in vitro activity against a range of aerobic and anaerobic gram-positive and gram-negative organisms. It possesses a high degree of stability in the presence of beta-lactamases including both penicillinases and cephalosporinase of gram-negative bacteria.
Cefotan is available as 1g and 2g strength vials in 10-count trays. It is intended for intravenous or intramuscular administration.
For more information call (856) 697-4397 or visit Teligent.com.